The Brexit project is ever changing and keeping up to date with how it impacts on the life sciences sector is a difficult task. Here, we have highlighted some Brexit information for life science companies and we assess its impact. Recently, discussions around the UK’s departure from the European Union reached another pivotal stage. EU Chief Negotiator Michel Barnier is due to publish a 120 page draft legal text that will map out the December 2017 agreement with the United Kingdom. This draft legal text will include unresolved and contentious issues such as that of the border between the Republic of Ireland and Northern Ireland. More importantly at this stage for the life sciences sector, the draft legal document should give insight into how companies will be able to trade between the EU27 and the UK during and after the mooted transition period. There is still a distinct possibility that the talks might collapse, over an issue such as the aforementioned Irish border issue or another issue, and the UK might leave the EU at the end of March next year without a trade deal or a transition period. Therefore, there is a need at this stage for pharmaceutical and medical device companies to be informed of current developments and to have a strategy that encompasses the many outcomes that remain on the negotiating table at the moment. It is essential for companies to have such scenarios mapped out to ensure that supply chains are not interrupted and that Brexit does not adversely impact on the commercial success of the company. Here, below, we have listed a wide range of Brexit resources that have been created by our expert team over the last two years. Our team have been working with our clients to ensure that they remain informed and that their companies are not impacted by the UK’s decision to leave the EU. If you would like to talk to us about Brexit or other regulatory issues then please call us at any time on 00353 52 61 76706.